Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JANX014 in Metastatic Castration-Resistant Prostate Cancer
NCT07545811Phase 1Recruiting
- Sponsor
- Janux Therapeutics
- Start
- Apr 2026
- Primary completion
- May 2028
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of JANX014 in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Janux Therapeutics. Primary endpoints: Incidence of Dose Limiting Toxicities at 2 years and Incidence of adverse events and Serious Adverse Events at 2 years. Started Apr 2026; status: recruiting.
02
Drugs
JANX014
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT07545811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07545811.